Brown Rudnick Provides IP Counsel to Aliada Therapeutics, Now in Acquisition by AbbVie for $1.4B

Brown Rudnick is day-to-day IP counsel for Aliada Therapeutics and represented Aliada in IP areas related to AbbVie's pending acquisition of the biotechnology company that is focused on developing therapies for central nervous system (CNS) diseases.

AbbVie announced on Oct. 28 an agreement under which the pharmaceutical giant will acquire Aliada for $1.4 billion in cash. The acquisition includes Aliada's lead asset, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development to treat Alzheimer's disease.

The transaction, which is expected to close by the end of the year, will strengthen AbbVie's R&D capabilities by leveraging Aliada's novel blood-brain barrier-crossing technology, the MODEL platform.

Founded in 2021, Aliada is a neuroscience-focused biotechnology company that leverages its MODEL platform to research and develop differentiated large molecule therapeutics for patients with neurological disorders and systemic disorders with CNS involvement.

The acquisition made headlines in The Wall Street Journal, Reuters and other news outlets.

Partner Adam Schoen leads the Brown Rudnick team serving as day-to-day IP counsel for Aliada and IP counsel in the AbbVie acquisition. The team also includes associate Robert B. Ruh III.